Plain-English translation of NCT07372040 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
When your heart can't pump well, fluid builds up in your body—causing shortness of breath, swelling, and other serious problems. This trial is testing whether adding , , or to your regular water pill (loop diuretic) helps remove that excess fluid more effectively and safely during a hospital stay.
Doctors currently use loop diuretics as the main treatment for fluid overload in acute heart failure, but some patients don't respond well enough or have side effects. This medication may help by working in a different way in the kidneys, potentially improving outcomes and safety for hospitalized patients.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of three medications—taken by mouth each morning for three days—alongside your regular diuretic therapy while in the hospital. The research team would monitor your symptoms, fluid levels, kidney function, and blood pressure during these three days and likely for a short time after to see how well the medication works and whether it causes any problems.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Egypt
Phase
Testing effectiveness
Sponsor
Tanta University
Enrollment target
~66 participants
Started
February 2026
Primary completion
February 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dalia A Gomaa, MSc in clinical pharmacy
Tanta University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.